To investigate the effectiveness and safety of romosozumab (ROMO) and teriparatide (TPTD) in postmenopausal women with osteoporosis in a clinical setting, with a focus on their implications for treatment strategies.
Key Findings:
ROMO resulted in significantly larger increases in BMD compared to TPTD at 12 months (FN: 4.8% vs 0.2%, TH: 5.7% vs 0.3%, LS: 13.7% vs 9.3%, P < .001).
Discontinuation rates were lower with ROMO than TPTD (P-value needed).
ROMO showed a lower incidence of cardiovascular adverse events compared to TPTD (P-value needed).
Treatment-naïve patients had higher BMD increases compared to previously treated patients with both ROMO and TPTD (P-value needed).
Interpretation:
ROMO is more effective than TPTD in increasing BMD in postmenopausal women with osteoporosis, with better adherence and a favorable safety profile, suggesting a potential shift in treatment protocols.
Limitations:
The study was observational and retrospective, which may introduce bias and limit causal inferences.
Exclusion of men and patients with high cardiovascular risk limits generalizability to the broader population.
Conclusion:
ROMO treatment yields greater increases in BMD and higher adherence compared to TPTD in postmenopausal women with osteoporosis.
